ライフサイエンスコーパス: decrease in FEV1

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 1.07 (95% CI: 1.03, 1.10) for asthma, a 9 ml decrease in FEV1 (95% CI: 2.0-15 mL decrease) and a 16 m

2 diameter exposure was associated with a 7.7% decrease in FEV1 (95% confidence interval = -11.8 to -3.

3 ith a significant improvement in the maximal decrease in FEV1 after exercise (P=0.003) and the time f

4 We calculated the percent decrease in FEV1 after provocation with ACh or Hist.

5 For every 200-ml decrease in FEV1, all-cause mortality increased by 11.0%

6 In contrast, for every 200-ml decrease in FEV1, all-cause mortality increased by only

7 tive concentration of allergen causing a 15% decrease in FEV1 (allergen PC15) that was maximal and ap

8 analyses, weight gain was associated with a decrease in FEV1 and health status among obese smokers a

9 rongly and independently correlated with the decrease in FEV1 and reactance of the respiratory system

10 Estimated decreases in FEV1 and FVC attributable to weight gain we

11 ce, even in subjects who did not reach a 20% decrease in FEV1 at the cumulative dose of 1 mg of metha

12 The GRS was significantly associated with decrease in FEV1: beta=-0.0012 (95% CI: -0.0019, -0.0006

13 For Ach, the percent decrease in FEV1 correlated with changes in Fres or R5-R

14 For Ach, this decrease in FEV1 correlated with changes in R20 and Fres

15 For Hist, this decrease in FEV1 correlated with changes in R5, R20, and

16 For Hist, the percent decrease in FEV1 correlated with changes in R5, R20, Fre

17 The primary end point was maximal decrease in FEV1 during 10 days after inoculation.

18 asthma diagnosis was associated with larger decreases in FEV1, FEF25-75, and FEV1/FVC ratio compared

19 crease in NO2 level was associated with a 5% decrease in FEV1/forced vital capacity ratio (beta = -0.

20 nse increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio).

21 er, decreased with long-term administration (decrease in FEV1 from morning to evening on day 1, 6+/-2

22 with asthma and the AA/AG genotypes had a 5% decrease in FEV1 /FVC (P<.001).

23 Higher body mass index was associated with a decrease in FEV1/FVC ratios among adolescents with insul

24 adolescents with MS had an approximately 2% decrease in FEV1/FVC ratios, adolescents with asthma had

25 ne for 4 h with exercise (responders, with a decrease in FEV1 > 15%; and non-responders, with a decre

26 tudy 1, there was a 17.1% maximum percentage decrease in FEV1 in the pitrakinra group; by contrast, t

27 study 2, there was a 4.4% average percentage decrease in FEV1 in the pitrakinra group; by contrast, t

28 The decrease in FEV1 inversely correlated with basal urinary

29 se in FEV1 > 15%; and non-responders, with a decrease in FEV1 < 5%).

30 nce, -0.01; 95% CI, -0.03 to 0.01; P = .57), decrease in FEV1 of 20% or greater (RD, 0.00; 95% CI, -0

31 27 (6%) sputum induction procedures showed a decrease in FEV1 of 20% or more.

32 cessive days of the MD exposure (mean +/- SD decrease in FEV1 of 25.4 +/- 18.0% across MD2 compared w

33 eceiving salmeterol had a maximal percentage decrease in FEV1 of less than 20%.

34 degree of bronchoconstriction at all times (decrease in FEV1 on day 1, 5+/-2 percent; on day 14, 10+

35 entration of histamine aerosol causing a 20% decrease in FEV1 (PC20) was less than 18 mg/ml).

36 of adenosine 5'-monophosphate causing a 20% decrease in FEV1 (PC20AMP).

37 centage inhibition in the maximal percentage decrease in FEV1; the area above the FEV1-time curve; an

38 cise (P=0.003) and the time from the maximal decrease in FEV1 to the return of lung function to withi

39 centage inhibition in the maximal percentage decrease in FEV1 was 57.2% in the montelukast group and

40 The decrease in FEV1 was greatest across Day 2 of the MD (MD

41 significant reductions in maximal percentage decrease in FEV1 were seen with both therapies.

42 Patients with asthma showed a 20%-36% decrease in FEV1, with significant decreases in the medi

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。